Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.

Accuracy of content

Information in these resources is the best available at the time of writing but, in this rapidly changing field, is subject to significant change with time.

Financial risk

Estimates of financial risk are based on our authors’ opinions and are highly sensitive to variation in the assumptions used to derive the estimates. We have used national figures; use of local figures will increase the reliability of these estimates. We explain our assumptions so you can adjust these if necessary.

Adaptation of content

The authors do not accept responsibility for accuracy of documents that are derived from this original publication.

Downloading and copying

If you download Prescribing Outlook resources you agree to abide by the following conditions.

This document is produced by the NHS for the NHS and is intended for use by individual NHS organisations exclusively for internal use within that organisation. The aim is to inform decisions about managed entry of new medicines, and medicines management more generally, within that organisation. The data within the document should not be used for commercial purposes or for any means of financial gain.

The document, and its contents, should not be posted on any website, copied or forwarded electronically outside your organisation, without express permission of the executive editors. Please contact nwmedinfo@nhs.net to request such permission.

Data Security

To prevent unauthorised access to Prescribing Outlook by non-NHS organisations, we encrypt it with a password. The password can be found on the webpage immediately above the link to the document. You will need to log in to the SPS website to see the password and the link.

Hyperlinking

We are happy for websites to hyperlink to any of our planning materials.

Prescribing Outlook 2024

Private: Annual medicines planning publication, Prescribing Outlook

Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.

Print this page